LLY · 8-K · 20260805PR000077
Regulatory Approval Milestones
ELI LILLY & Co · 2026-08-05 · Importance 34 · Surprise 42 · No source text
The U.S. FDA approved Ebglyss for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis. The European Commission approved Jaypirca as monotherapy for adults with chronic lymphocytic leukemia across all lines of therapy, following a positive CHMP recommendation. Lilly also submitted orforglipron for type 2 diabetes in the United States and received FDA Breakthrough Therapy designation for olomorasib in previously treated KRAS G12C-mutant advanced pancreatic cancer.
Key facts
- Lilly submitted orforglipron for type 2 diabetes in the U.S. source
- Lilly's U.S. FDA approved Ebglyss for one maintenance dose every eight weeks in moderate-to-severe atopic dermatitis. source
- European Commission recommended approval of Jaypirca as monotherapy for adults with chronic lymphocytic leukemia across all lines of therapy (CHMP recommendation referenced). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Lilly submitted orforglipron for type 2 diabetes in the U.S. |
| revenue | positive | probable | — | Lilly's U.S. FDA approved Ebglyss for one maintenance dose every eight weeks in moderate-to-severe atopic dermatitis. |
| revenue | positive | probable | — | European Commission recommended approval of Jaypirca as monotherapy for adults with chronic lymphocytic leukemia across all lines of… |